Leica Biosystems to Acquire Aperio

| August 21, 2012

Nussloch, Germany / Vista, CA (August 21, 2012)
Leica Biosystems announced that an affiliate has entered into a definitive
agreement to acquire Aperio, a leading provider of ePathology solutions.

Aperio will be integrated into Leica Biosystems, a leader in
anatomical pathology solutions. Together, the two businesses will leverage each
other’s strengths to grow and expand digital pathology into the global Life
Science and Healthcare markets. The integrated business will provide industry
leading solutions in each step of the anatomical pathology workflow, from sample
preparation and staining, to imaging and reporting. The company will continue to
offer both the Aperio and the existing Leica portfolio of Digital Pathology
solutions, so that customers will enjoy more freedom to choose a solution that
meets their individual needs. 

Aperio is a global leader in digital pathology, with the
largest installed base of systems in both Life Science and Healthcare. Aperio
ePathology Solutions include whole slide scanners, a NETWORK solution that
enables remote, real-time viewing and easy distribution of images for peer
review, collaboration and consultation. Its PRECISION solution provides
pathologists with easy-to-use quantitative image analysis to improve research
and clinical productivity, reproducibility, and consistency. Customers include
clinicians and researchers working in hospitals, reference laboratories, pharma
and research institutions.

“We are excited to acquire Aperio, because of its leadership
in digital pathology, innovative product portfolio, and its very experienced
global team. We share the commitment to advancing cancer diagnostics to improve
lives. This acquisition positions us to better address the growing demand for
personalized medicine and the increasing challenge of staff shortage in the
global pathology market. Together we offer the market an end-to-end solution
from the time that the specimen is collected to the time that the results are
delivered, to help our customers improve workflow efficiency and diagnostic
confidence,” said Arnd Kaldowski, President of Leica Biosystems.

“We believe that Aperio will benefit from the heritage, deep
pathology expertise, and strong brand recognition of Leica Biosystems”, said
David Schlotterbeck, CEO of Aperio. “The combined product offerings and improved
reach into the diagnostic market will make our ePathology Solutions more widely
available.  We see our goals as synergistic and together we can address the
regional and global imbalances of pathology expertise available for patient care
and research.”

About Leica Biosystems

Leica Biosystems offers histopathology laboratories the most
extensive product range with industry leading solutions for each workflow step,
to enable the improvement of workflow efficiency and diagnostic confidence.
Leica Biosystems is represented in over 100 countries. It has manufacturing
facilities in 7 countries, sales and service organizations in 19 countries, and
an international network of dealers. The company is headquartered in Nussloch,
Germany. Further information can be found at www.LeicaBiosystems.com

About Aperio

For over a decade, Aperio has advanced the technology that
enables glass slides to be digitized and securely shared with others. Aperio
products are transforming the practice of pathology in hospitals, reference
labs, and pharmaceutical and research institutions around the world. From the
moment glass slides are elevated to eSlides, Aperio ePathology Solutions equip
pathologists with the power to evaluate, engage, and excel like never before.
The NETWORK enables remote, simultaneous, real-time viewing and easy
distribution for consults and collaboration. PRECISION tools empower
pathologists with advanced analytic capabilities. An interoperable, scalable,
and secure web-based software platform facilitates integration with existing
systems. With Aperio ePathology Solutions, organizations can optimize their
pathology operations for transparency, consistency, and efficiency to support
patient care, personalized medicine, and research. For clearance updates,
specific product indications, and more information please visit www.aperio.com


Category: Digital Pathology News, Pathology News

Comments are closed.